Logo image of ZVRA

ZEVRA THERAPEUTICS INC (ZVRA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ZVRA - US4884452065 - Common Stock

8.49 USD
-0.14 (-1.62%)
Last: 1/9/2026, 5:29:40 PM
8.65 USD
+0.16 (+1.88%)
After Hours: 1/9/2026, 5:29:40 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ZVRA. ZVRA was compared to 191 industry peers in the Pharmaceuticals industry. ZVRA has a bad profitability rating. Also its financial health evaluation is rather negative. ZVRA is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ZVRA was profitable.
ZVRA had a negative operating cash flow in the past year.
ZVRA had negative earnings in each of the past 5 years.
ZVRA had negative operating cash flow in 4 of the past 5 years.
ZVRA Yearly Net Income VS EBIT VS OCF VS FCFZVRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of ZVRA (13.08%) is better than 93.72% of its industry peers.
With an excellent Return On Equity value of 26.53%, ZVRA belongs to the best of the industry, outperforming 93.19% of the companies in the same industry.
Industry RankSector Rank
ROA 13.08%
ROE 26.53%
ROIC N/A
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZVRA Yearly ROA, ROE, ROICZVRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

ZVRA's Profit Margin of 41.86% is amongst the best of the industry. ZVRA outperforms 97.38% of its industry peers.
ZVRA has a better Gross Margin (93.88%) than 95.29% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 41.86%
GM 93.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZVRA Yearly Profit, Operating, Gross MarginsZVRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

ZVRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZVRA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ZVRA has more shares outstanding
The debt/assets ratio for ZVRA is higher compared to a year ago.
ZVRA Yearly Shares OutstandingZVRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ZVRA Yearly Total Debt VS Total AssetsZVRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of 0.72, we must say that ZVRA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.72, ZVRA is in line with its industry, outperforming 49.74% of the companies in the same industry.
ZVRA has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
ZVRA's Debt to Equity ratio of 0.46 is on the low side compared to the rest of the industry. ZVRA is outperformed by 61.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Altman-Z 0.72
ROIC/WACCN/A
WACC9.73%
ZVRA Yearly LT Debt VS Equity VS FCFZVRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 8.62 indicates that ZVRA has no problem at all paying its short term obligations.
ZVRA has a Current ratio of 8.62. This is in the better half of the industry: ZVRA outperforms 75.39% of its industry peers.
A Quick Ratio of 8.57 indicates that ZVRA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 8.57, ZVRA is doing good in the industry, outperforming 75.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.62
Quick Ratio 8.57
ZVRA Yearly Current Assets VS Current LiabilitesZVRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 122.84% over the past year.
Looking at the last year, ZVRA shows a very strong growth in Revenue. The Revenue has grown by 240.47%.
The Revenue has been growing by 12.96% on average over the past years. This is quite good.
EPS 1Y (TTM)122.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.55%
Revenue 1Y (TTM)240.47%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%605.36%

3.2 Future

The Earnings Per Share is expected to grow by 28.20% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 76.65% on average over the next years. This is a very strong growth
EPS Next Y157.77%
EPS Next 2Y50.05%
EPS Next 3Y39.67%
EPS Next 5Y28.2%
Revenue Next Year388.89%
Revenue Next 2Y165.06%
Revenue Next 3Y121.31%
Revenue Next 5Y76.65%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ZVRA Yearly Revenue VS EstimatesZVRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ZVRA Yearly EPS VS EstimatesZVRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80 -100

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 18.87, which indicates a rather expensive current valuation of ZVRA.
82.20% of the companies in the same industry are more expensive than ZVRA, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.19. ZVRA is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 14.93, which indicates a correct valuation of ZVRA.
Based on the Price/Forward Earnings ratio, ZVRA is valued cheaper than 82.20% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.88, ZVRA is valued a bit cheaper.
Industry RankSector Rank
PE 18.87
Fwd PE 14.93
ZVRA Price Earnings VS Forward Price EarningsZVRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZVRA Per share dataZVRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ZVRA's earnings are expected to grow with 39.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y50.05%
EPS Next 3Y39.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZVRA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ZEVRA THERAPEUTICS INC

NASDAQ:ZVRA (1/9/2026, 5:29:40 PM)

After market: 8.65 +0.16 (+1.88%)

8.49

-0.14 (-1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-09 2026-03-09/amc
Inst Owners70.03%
Inst Owner ChangeN/A
Ins Owners0.69%
Ins Owner Change11.79%
Market Cap477.99M
Revenue(TTM)84.39M
Net Income(TTM)35.33M
Analysts84.29
Price Target23.31 (174.56%)
Short Float %12.54%
Short Ratio5.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)25.59%
Min EPS beat(2)-20.8%
Max EPS beat(2)71.99%
EPS beat(4)2
Avg EPS beat(4)13.08%
Min EPS beat(4)-67.34%
Max EPS beat(4)71.99%
EPS beat(8)3
Avg EPS beat(8)-5.61%
EPS beat(12)4
Avg EPS beat(12)-9.16%
EPS beat(16)5
Avg EPS beat(16)-12.64%
Revenue beat(2)1
Avg Revenue beat(2)4.28%
Min Revenue beat(2)-4.04%
Max Revenue beat(2)12.59%
Revenue beat(4)3
Avg Revenue beat(4)14.7%
Min Revenue beat(4)-4.04%
Max Revenue beat(4)32.28%
Revenue beat(8)5
Avg Revenue beat(8)4.12%
Revenue beat(12)7
Avg Revenue beat(12)14.01%
Revenue beat(16)9
Avg Revenue beat(16)10.43%
PT rev (1m)0%
PT rev (3m)-3.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)278.95%
EPS NY rev (1m)0%
EPS NY rev (3m)6.44%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-0.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.73%
Valuation
Industry RankSector Rank
PE 18.87
Fwd PE 14.93
P/S 5.66
P/FCF N/A
P/OCF N/A
P/B 3.59
P/tB 3.93
EV/EBITDA N/A
EPS(TTM)0.45
EY5.3%
EPS(NY)0.57
Fwd EY6.7%
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS1.5
BVpS2.37
TBVpS2.16
PEG (NY)0.12
PEG (5Y)N/A
Graham Number4.89
Profitability
Industry RankSector Rank
ROA 13.08%
ROE 26.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 41.86%
GM 93.88%
FCFM N/A
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 128.58%
Cap/Sales 8.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.62
Quick Ratio 8.57
Altman-Z 0.72
F-Score6
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)44.3%
Cap/Depr(5y)36.5%
Cap/Sales(3y)9.12%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)122.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.55%
EPS Next Y157.77%
EPS Next 2Y50.05%
EPS Next 3Y39.67%
EPS Next 5Y28.2%
Revenue 1Y (TTM)240.47%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%605.36%
Revenue Next Year388.89%
Revenue Next 2Y165.06%
Revenue Next 3Y121.31%
Revenue Next 5Y76.65%
EBIT growth 1Y66.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.53%
EBIT Next 3Y40.04%
EBIT Next 5Y32.31%
FCF growth 1Y-36.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.98%
OCF growth 3YN/A
OCF growth 5YN/A

ZEVRA THERAPEUTICS INC / ZVRA FAQ

What is the fundamental rating for ZVRA stock?

ChartMill assigns a fundamental rating of 4 / 10 to ZVRA.


What is the valuation status for ZVRA stock?

ChartMill assigns a valuation rating of 5 / 10 to ZEVRA THERAPEUTICS INC (ZVRA). This can be considered as Fairly Valued.


What is the profitability of ZVRA stock?

ZEVRA THERAPEUTICS INC (ZVRA) has a profitability rating of 3 / 10.


What is the earnings growth outlook for ZEVRA THERAPEUTICS INC?

The Earnings per Share (EPS) of ZEVRA THERAPEUTICS INC (ZVRA) is expected to grow by 157.77% in the next year.